Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl…
Bristol Myers Squibb and Acceleron Pharma Inc. announced the first data from the Phase 2 BEYOND study evaluating Reblozyl(luspatercept-aamt), a first-in-class erythroid maturation…
Read More...
Read More...
